Observational Study of Need for Thrombolytic Therapy and Incidence of Bacteremia using Taurolidine‐CITRATE (cas 13754-17-1)‐Heparin, Taurolidine‐CITRATE (cas 13754-17-1) and Heparin Catheter Locks in Patients Treated with Hemodialysis

Add time:09/25/2019    Source:infona.pl

Catheter‐related blood stream infections may be reduced by interdialytic locking with Taurolidine, a nontoxic antimicrobial agent. A formulation of 1.35% Taurolidine in 4% citrate (TC) is associated with a greater need for thrombolysis to maintain catheter patency than 5000 U/ml heparin. Our aim was to determine whether addition of 500 Units/ml of heparin to TC reduces the need for thrombolysis. TCH (1.35% taurolidine, 4% citrate and 500 U/ml heparin) was compared to TC and Heparin 5000 U/ml using retrospective data. Hundred and six adult hemodialysis patients with internal jugular tunnelled intravascular catheters using TCH were compared with 34 patients using TC and 34 patients using heparin 5000 U/ml respectively. Outcomes were time to first use of thrombolysis and bacteremia rates.TCH reduced the need for thrombolysis compared to TC (hazard ratio, 0.2; 95%CI: 0.06, 0.5; p < 0.001) and was not significantly different from heparin 5000 U/ml (hazard ratio, 1.4; 95%CI: 0.5, 3.9; p = 0.5). The bacteremia rates from all causes were 1.33, 1.22 and 3.25 per 1000 catheter‐ days (p < 0.001) in the TCH, TC and heparin groups respectively. Addition of 500 U/ml heparin to TC reduces the need for thrombolysis without increasing bacteremia and may achieve patency comparable to heparin 5000 U/ml.

We also recommend Trading Suppliers and Manufacturers of CITRATE (cas 13754-17-1). Pls Click Website Link as below: cas 13754-17-1 suppliers

Prev:Electro-oxidation of meso-erythritol on platinum in acid medium: analysis of the reaction products
Next:A randomized controlled trial of the efficacy of rosiglitazone and clomiphene CITRATE (cas 13754-17-1) versus metformin and clomiphene CITRATE (cas 13754-17-1) in women with clomiphene CITRATE (cas 13754-17-1)–resistant polycystic ovary syndrome)